A detailed history of State Of Wisconsin Investment Board transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, State Of Wisconsin Investment Board holds 143,300 shares of AVIR stock, worth $492,952. This represents 0.0% of its overall portfolio holdings.

Number of Shares
143,300
Previous 128,900 11.17%
Holding current value
$492,952
Previous $520,000 8.85%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.31 - $4.04 $47,664 - $58,176
14,400 Added 11.17%
143,300 $474,000
Q1 2024

May 14, 2024

SELL
$3.09 - $4.56 $3,090 - $4,560
-1,000 Reduced 0.77%
128,900 $520,000
Q4 2023

Feb 12, 2024

BUY
$2.8 - $3.35 $18,760 - $22,445
6,700 Added 5.44%
129,900 $396,000
Q3 2023

Nov 14, 2023

SELL
$3.0 - $3.79 $104,700 - $132,271
-34,900 Reduced 22.07%
123,200 $369,000
Q2 2023

Aug 14, 2023

SELL
$3.21 - $5.06 $105,528 - $166,347
-32,875 Reduced 17.21%
158,100 $591,000
Q1 2023

May 15, 2023

SELL
$3.0 - $4.97 $72,831 - $120,656
-24,277 Reduced 11.28%
190,975 $639,000
Q4 2022

Feb 14, 2023

BUY
$4.35 - $6.17 $148,704 - $210,921
34,185 Added 18.88%
215,252 $1.04 Million
Q3 2022

Nov 14, 2022

BUY
$5.49 - $8.79 $30,332 - $48,564
5,525 Added 3.15%
181,067 $1.03 Million
Q2 2022

Aug 15, 2022

BUY
$5.33 - $8.18 $62,584 - $96,049
11,742 Added 7.17%
175,542 $1.25 Million
Q1 2022

May 13, 2022

BUY
$5.5 - $9.19 $441,100 - $737,038
80,200 Added 95.93%
163,800 $1.18 Million
Q2 2021

Aug 12, 2021

BUY
$19.22 - $59.08 $1.22 Million - $3.75 Million
63,500 Added 315.92%
83,600 $1.8 Million
Q4 2020

Feb 03, 2021

BUY
$26.36 - $41.78 $529,836 - $839,778
20,100 New
20,100 $840,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $286M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track State Of Wisconsin Investment Board Portfolio

Follow State Of Wisconsin Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wisconsin Investment Board with notifications on news.